This is an old revision of this page, as edited by Whywhenwhohow (talk | contribs) at 05:40, 21 December 2024 (create). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 05:40, 21 December 2024 by Whywhenwhohow (talk | contribs) (create)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Veterinary medicationPharmaceutical compound
Clinical data | |
---|---|
Trade names | Zenrelia |
Other names | LY-3411067 |
License data |
|
Routes of administration | By mouth |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
PubChem CID | |
UNII | |
Chemical and physical data | |
Formula | C17H17N7O2S |
Molar mass | 383.43 g·mol |
Ilunocitinib, sold under the brand name Zenrelia, is a veterinary medication used for the treatment of pruritus (itching) in dogs.
It was approved for medical use in the United States in September 2024, and in Canada in December 2024.
Medical uses
Ilunocitinib is indicated for the control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least twelve months of age.
Contraindications
It is not safe to administer vaccines to dogs that are concurrently receiving ilunocitinib.
References
- ^ "Notice: Multiple additions to the Prescription Drug List (PDL) [2024-12-20]". Health Canada. 20 December 2024. Retrieved 21 December 2024. Text was copied from this source. Reproduction is authorized provided the source is acknowledged.
- "Zenrelia". U.S. Food and Drug Administration (FDA). Retrieved 21 December 2024.
- ^ https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/15865
- "FDA Approves New Treatment for Allergic Skin Conditions in Dogs". U.S. Food and Drug Administration (FDA). 19 September 2024. Retrieved 21 December 2024.
This article incorporates text from this source, which is in the public domain.
- ^ "Dear Veterinarian Letter regarding important safety information associated with the use of Zenrelia (ilunocitinib tablets) for controlling pruritus associated with allergic dermatitis and atopic dermatitis in dogs". U.S. Food and Drug Administration (FDA). 1 October 2024. Retrieved 21 December 2024.
This article incorporates text from this source, which is in the public domain.
Immunosuppressive drugs / Immunosuppressants (L04) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Intracellular (initiation) |
| ||||||||||||||
Intracellular (reception) |
| ||||||||||||||
Extracellular |
| ||||||||||||||
Unsorted |
|
![]() | This veterinary medicine–related article is a stub. You can help Misplaced Pages by expanding it. |